Table 1.
Associations of the interaction between ANLN and KDR with histopathological parameters. The expression level, “high” or “low,” refers to that of ANLN and KDR, respectively, in the represented order. “ER,” “PR,” and “HER2” are cell receptors canonically used for breast cancer subtyping, “T” represents the size of the original tumor and whether it has invaded nearby tissue, “N” describes the nearby lymph nodes involved, “TNM stage” is an international standard for classifying the extent of spread of cancer based on “T,” “N,” and “M” (“M” describes distant metastasis). “Subtype” refers to PAM50 molecular subtyping, and ER-PR-HER2 histochemistry staining system was used to assess the subtyping status if PAM50 subtyping was not available; “LumAorB” means that PAM50 is “NA,” ER or PR is positive, HER2 is negative; “TNG” is short for triple negative group. Patients were analyzed by ANLN and KDR protein expression, with the number and percentage of patients in each category being summarized as “No.” and “(%).” Chi-squared test and 1,000 permutations of Monte Carlo simulations were conducted to assess the significance of associations of the two-gene interaction with each histopathological parameter.
| ANLN:KDR | All | High:High | High:Low | Low:High | Low:Low | Chi-square | Monte Carlo | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No. | (%) | No. | (%) | No. | (%) | No. | (%) | No. | (%) | p | p | |
| ER | ||||||||||||
| − | 95 | 25.13% | 28 | 28.57% | 41 | 46.07% | 7 | 6.09% | 19 | 25.00% | 1.91E−09 | 1.00E−04 |
| + | 283 | 74.87% | 70 | 71.43% | 48 | 53.93% | 108 | 93.91% | 57 | 75.00% | ||
| PR | ||||||||||||
| − | 148 | 39.05% | 44 | 44.90% | 48 | 53.93% | 21 | 18.26% | 35 | 45.45% | 5.49E−07 | 1.00E−04 |
| + | 231 | 60.95% | 54 | 55.10% | 41 | 46.07% | 94 | 81.74% | 42 | 54.55% | ||
| HER2 | ||||||||||||
| − | 203 | 75.46% | 55 | 82.09% | 44 | 72.13% | 71 | 83.53% | 33 | 58.93% | 4.20E−03 | 5.20E−03 |
| + | 66 | 24.54% | 12 | 17.91% | 17 | 27.87% | 14 | 16.47% | 23 | 41.07% | ||
| T | ||||||||||||
| 1 | 90 | 23.50% | 21 | 21.21% | 16 | 18.18% | 34 | 29.31% | 19 | 23.75% | 0.2776657 | 0.288471153 |
| 2+ | 293 | 76.50% | 78 | 78.79% | 72 | 81.82% | 82 | 70.69% | 61 | 76.25% | ||
| N | ||||||||||||
| 0 | 178 | 47.21% | 53 | 54.08% | 39 | 44.83% | 53 | 47.32% | 33 | 41.25% | 0.3624281 | 0.360863914 |
| 1+ | 199 | 52.79% | 45 | 45.92% | 48 | 55.17% | 59 | 52.68% | 47 | 58.75% | ||
| TNM Stage | ||||||||||||
| 1 | 77 | 20.48% | 17 | 17.35% | 12 | 13.95% | 32 | 28.07% | 16 | 20.51% | 0.0365787 | 0.0359964 |
| 2 | 213 | 56.65% | 65 | 66.33% | 46 | 53.49% | 58 | 50.88% | 44 | 56.41% | ||
| 3 | 86 | 22.87% | 16 | 16.33% | 28 | 32.56% | 24 | 21.05% | 18 | 23.08% | ||
| Subtype | ||||||||||||
| Basal | 28 | 7.37% | 11 | 11.11% | 10 | 11.36% | 2 | 1.74% | 5 | 6.41% | 2.63E−07 | 1.00E−04 |
| Her2 | 23 | 6.05% | 4 | 4.04% | 11 | 12.50% | 1 | 0.87% | 7 | 8.97% | ||
| LumA | 195 | 51.32% | 50 | 50.51% | 36 | 40.91% | 77 | 66.96% | 32 | 41.03% | ||
| LumAorB | 22 | 5.79% | 10 | 10.10% | 2 | 2.27% | 6 | 5.22% | 4 | 5.13% | ||
| LumB | 76 | 20.00% | 14 | 14.14% | 12 | 13.64% | 27 | 23.48% | 23 | 29.49% | ||
| TNG | 36 | 9.47% | 10 | 10.10% | 17 | 19.32% | 2 | 1.74% | 7 | 8.97% | ||